Comparative tumor dose from 131I-labeled polyclonal anti-ferritin, anti-AFP, and anti-CEA in primary liver cancers.
Comparative tumor dose from 131I-labeled polyclonal anti-ferritin, anti-AFP, and anti-CEA in primary liver cancers.
复制标题
原发性肝癌中 131I 标记的多克隆抗铁蛋白、抗 AFP 和抗 CEA 的肿瘤剂量比较。
DOI：
10.1089/cdd.1984.1.321
复制
发表时间：
1984
期刊：
影响因子：
--
通讯作者：
Order,SE
中科院分区：
文献类型：
--
作者：
Leichner,PK;Klein,JL;Fishman,EK;Siegelman,SS;Ettinger,DS;Order,SE
本文报告了30例肝癌和5例原发性肝胆管癌患者接受~（131）I标记多克隆抗体治疗的剂量学研究结果。研究包括通过X射线CT扫描计算肝脏和肿瘤体积，体内定量肝脏肿瘤和正常肝脏组织中放射性标记抗体的活性，以及有效半衰期测量。用~（131）I标记的多克隆抗铁蛋白抗体对22例肝癌患者进行治疗。对5例AFP阳性的肝癌患者进行了抗甲胎蛋白（AFP）治疗。3例AFP阳性肝癌患者同时接受了131 I标记的抗铁蛋白和抗AFP。对5例胆管癌患者进行了~（131）I标记的抗癌胚抗原（CEA）治疗。对于第0天30 mCi和第5天20 mCi的给药活性，肝癌的辐射剂量平均值约为抗铁蛋白1100拉德，抗AFP 350拉德，抗铁蛋白和抗AFP组合960拉德。因此，多克隆抗铁蛋白抗体已成为肝癌治疗的首选抗体。用~（131）I标记的抗CEA抗体对胆管癌进行放射治疗，第0天放射性活度为20 mCi，第5天放射性活度为10 mCi，放射剂量约为620拉德。这些注射时间表的全身照射范围从30到50拉德。
Results of dosimetric studies are reported for 30 patients with hepatoma and 5 patients with primary hepatic cholangiocarcinoma who received treatment with131I-labeled polyclonal antibodies. Studies included liver and tumor volume computations from X-ray CT scans,in vivoquantitation of the activity of radiolabeled antibodies in hepatic tumors and normal liver tissue, and effective half-life measurements. Twenty-two patients with hepatoma were administered131I-labeled polyclonal anti-ferritin. Five hepatoma patients, who were AFP-positive, were administered anti-α-fetoprotein (AFP). Three patients with AFP-positive hepatomas received both131I-labeled anti-ferritin and anti-AFP in a bolus. The five cholangiocarcinoma patients were treated with131I-labeled anti-carcinoembryonic antigen (CEA). For administered activities of 30 mCi on day 0 and 20 mCi on day 5, mean values of the radiation dose to hepatomas were approximately 1100 rads for anti-ferritin, 350 rads for anti-AFP, and 960 rads for the combination of anti-ferritin and anti-AFP. Polyclonal anti-ferritin has, therefore, become the antibody of choice in the treatment of hepatoma. The radiation dose to cholangiocarcinomas from131I-labeled anti-CEA and administered activities of 20 mCi on day 0 and 10 mCi on day 5 was approximately 620 rads. Total-body irradiation for these injection schedules ranged from 30 to 50 rads.